Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 1992-09-08 (33 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: GUITRES (33230), Gironde
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL PHARMACIE ROSSIGNOL : revenue, balance sheet and financial ratios
EURL PHARMACIE ROSSIGNOL is a French company
founded 33 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in GUITRES (33230),
this company of category PME
shows in 2022 a revenue of 1.1 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE ROSSIGNOL (SIREN 388703027)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
1 076 912 €
N/C
N/C
N/C
N/C
N/C
Net income
90 974 €
64 942 €
77 537 €
117 501 €
41 682 €
42 641 €
58 284 €
61 140 €
80 348 €
EBITDA
N/C
N/C
N/C
127 205 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
10.9%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, EURL PHARMACIE ROSSIGNOL generates positive net income of 91 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 80 k€ -> 91 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
90 974 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 465%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 15%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
464.65%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
15.238%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
403.606
514.056
527.486
703.987
748.595
293.059
479.043
575.734
464.65
Financial autonomy
17.034
13.646
13.154
10.78
9.165
20.006
13.812
11.644
15.238
Repayment capacity
None
None
None
None
None
3.349
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
11.604%
None%
None%
None%
Sector positioning
Debt ratio
464.652025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Watch
In 2025, the debt ratio of EURL PHARMACIE ROSSIGNOL (464.65) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
Financial autonomy
15.24%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Watch
In 2025, the financial autonomy of EURL PHARMACIE ROSSIGNOL (15.2%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 209.72. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
151.713
142.86
133.864
169.191
121.113
97.918
125.062
136.791
209.719
Interest coverage
None
None
None
None
None
0.0
None
None
None
Sector positioning
Liquidity ratio
209.722025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good+36 pts over 3 years
In 2025, the liquidity ratio of EURL PHARMACIE ROSSIGNOL (209.72) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 119 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 701 days. Excellent situation: suppliers finance 582 days of the operating cycle (retail model).
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
119 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
701 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution EURL PHARMACIE ROSSIGNOL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
1 292 €
0 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
23
0
0
0
Customer payment term (days)
0
0
0
0
264
3
131
177
119
Supplier payment term (days)
0
0
0
0
963
32
662
946
701
Positioning of EURL PHARMACIE ROSSIGNOL in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of EURL PHARMACIE ROSSIGNOL is estimated at
1 445 132 €
(range 980 673€ - 2 267 612€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
980k€1445k€2267k€
1 445 132 €Range: 980 673€ - 2 267 612€
NAF 5 année 2025
Valuation method used
Net Income Multiple
90 974 €
×
15.9x
=1 445 133 €
Range: 980 674€ - 2 267 612€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE ROSSIGNOL with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE ROSSIGNOL
What is the revenue of EURL PHARMACIE ROSSIGNOL ?
The revenue of EURL PHARMACIE ROSSIGNOL in 2022 is 1.1 M€.
Is EURL PHARMACIE ROSSIGNOL profitable?
Yes, EURL PHARMACIE ROSSIGNOL generated a net profit of 91 k€ in 2025.
Where is the headquarters of EURL PHARMACIE ROSSIGNOL ?
The headquarters of EURL PHARMACIE ROSSIGNOL is located in GUITRES (33230), in the department Gironde.
Where to find the tax return of EURL PHARMACIE ROSSIGNOL ?
The tax return of EURL PHARMACIE ROSSIGNOL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE ROSSIGNOL operate?
EURL PHARMACIE ROSSIGNOL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart